Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib

Jorge J. Castillo, Jithma P. Abeykoon, Joshua N. Gustine, Saurabh Zanwar, Kirsten Mein, Catherine A. Flynn, Maria G. Demos, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nickolas Tsakmaklis, Rebecca King, Guang Yang, Zachary R. Hunter, Ranjana H. Advani, Maria Lia Palomba, Stephen M. Ansell, Morie A. Gertz, Prashant KapoorSteven P. Treon

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib'. Together they form a unique fingerprint.

Medicine & Life Sciences